1. Introduction {#sec1}
===============

Genotoxicity assessments are performed to detect whether a compound can induce direct or indirect DNA damage that may result in sequence alterations, loss of heterozygosity, and chromosome disorders ([@bib30]; [@bib33]). These events play an important role in many malignancies and induce heritable effects leading to congenital disorders ([@bib29]; [@bib8]). The evaluation of potential genotoxic effects is essential in the risk/benefit analysis of new drugs as well as for preparations already used in traditional medicine ([@bib24]; [@bib6]). International regulatory agencies have validated and recommend various genetic tests for genotoxic assessment, such as comet and micronucleus assays ([@bib11]).

The micronucleus test is based on the detection of DNA breaks that result in chromosome fragments which are not included in the nucleus during mitosis, forming an additional nucleus ([@bib19]). The comet assay is a technique used for detecting the presence of single strand breaks of DNA at alkali-sensitive sites or sites of incomplete excision repair in mammalian cells ([@bib19]). These tests have been used to analyze the toxicity ([@bib2]; [@bib22]; [@bib25]) as well as anti-genotoxic, anti-mutagenic, and anti-carcinogenic effects ([@bib10]; [@bib14]) of extracts and isolated compounds from plants.

*Pilosocereus gounellei* (Cactaceae), popularly known in Brazil as xique-xique, is a plant used in traditional medicine to treat perforations in the upper and lower limbs, as well as to produce anti-inflammatory preparations ([@bib1]; [@bib27]). Acute toxicity evaluation of a saline extract from *P. gounellei* stem showed that it did not promote adverse effects on survival, motor coordination, or the hematological, biochemical, and histological parameters of mice. This extract also did not present significant toxic effects when administered over 28 consecutive days and was reported to have antinociceptive and antipyretic activities ([@bib21], [@bib20]). Nonetheless, no scientific studies are available to date that rule out the genotoxic potential of *P. gounellei*. Thus, in this study, we aimed to evaluate the genotoxicity of the saline extract from *P. gounellei* through micronucleus and comet assays, as well as investigate its possible chemopreventive action against cyclophosphamide-induced DNA damage.

2. Materials and methods {#sec2}
========================

2.1. Plant material {#sec2.1}
-------------------

The stem of *P. gounellei* was collected at Limoeiro, Pernambuco, Brazil, under the authorization (number 36301) of the *Instituto Chico Mendes de Conservação da Biodiversidade* (ICMBio). The collection was recorded (ADF1667) in the *Sistema Nacional de Gestão do Patrimônio Genético e do Conhecimento Tradicional Associado* (SisGen) and a voucher specimen (no. 82,853) was deposited at the herbarium "UFP -- Geraldo Mariz" in the *Universidade Federal de Pernambuco* (UFPE). The stem had its thorns separated from the core (marrow), which was then maintained at 28 °C for 72 h. Next, the dried core (20 g) was crushed and homogenized in 150 mM NaCl (200 mL) for 16 h at 28 °C by magnetic stirring. The suspension was then centrifuged (3,000 g, 15 min, 25 °C) and the supernatant corresponded to the saline extract ([@bib21]).

2.2. Animals {#sec2.2}
------------

All the experiments were approved by the Ethics Committee on Animal Use of UFPE (process no. 23076.048175/2015-12). Male Swiss albino mice (*Mus musculus*) weighing 30--35 g were obtained from the vivarium of the *Laboratório de Imunopatologia Keizo Asami* of UFPE and used in experiments after a one-week adaptation period in the laboratory of animal experimentation at the *Departamento de Bioquímica* of UFPE, where they were kept under a 12/12 h light/dark cycle at 22 °C. Water and food (Labina, Purina, Brazil) were available *ad libitum.*

2.3. Evaluation of the genotoxicity of *P. gounellei* stem extract {#sec2.3}
------------------------------------------------------------------

### 2.3.1. Treatments {#sec2.3.1}

The mice were divided into experimental groups of 10 animals each. The extract was dissolved in saline solution (0.9% NaCl) and administered by gavage in a single dose of 0.1 mL at 500, 1,000 and 2,000 mg/kg body weight (b.w). These doses were selected based on the previous acute toxicity study ([@bib21]) and following the limit recommended by [@bib17]. The negative control group received only saline solution *per os* and the positive control group received an intraperitoneal injection of cyclophosphamide (CPA; Sigma-Aldrich, USA), dissolved in sterile deionized water, at 80 mg/kg b.w ([@bib4]).

### 2.3.2. Micronucleus test {#sec2.3.2}

The assay was carried out following the protocol described by [@bib13]. Five mice of each group were euthanized by cervical dislocation 24 h after the treatment and the other five after 48 h. Saline solution (2 mL) was used to collect the bone marrow from the femur. After centrifugation (7 min), 10 μL of bone marrow or blood was placed on three slides and stained with acridine orange and the presence of micronuclei ([Figure 1](#fig1){ref-type="fig"}) was evaluated using a fluorescence microscope (Olympus BX 50). For each slide, 2000 polychromatic erythrocytes were counted by a blinded researcher (6,000 cells/animal). The number of micronucleated polychromatic erythrocytes (MNPCE) was determined, as well as the ratio between polychromatic (PCE) and normochromatic (NCE) erythrocytes.Figure 1A representative image of a micronucleated polychromatic erythrocyte (MNPCE) stained with acridine orange, visualized under fluorescence microscope, with the micronucleus pointed by the arrow.Figure 1

### 2.3.3. Comet assay {#sec2.3.3}

Four or twenty-four hours after the treatment, samples of peripheral blood from the orbital plexus were collected from five mice. Bone marrow samples of ten mice per group were also collected after 24 h and analyzed. A hemocytometer was used to count the cells, which had their viability determined by trypan blue exclusion assay. Cells were only used if viability was \>90%. The comet assay was then carried out according to [@bib36]. The cells were evaluated in the fluorescence microscope (400× magnification) with excitation filter set at 515--560 nm and emission filter at 590 nm. In a blind analysis, individual nucleoids were scored, examining 200 randomly selected and non-overlapping cells per animal. The tail size and the diameter of the head (nucleus) were observed and used to score the cells according to [@bib7]: class 0 -- no tail; class 1 -- tail shorter than the head diameter; 2 -- tail length measuring 1--2 times the head diameter; 3 -- tail length measuring more than twice the head diameter. Total score for 200 comets was calculated by multiplying the number of cells in each class by the respective class number (0, 1, 2 or 3).

2.4. Evaluation of the anti-genotoxic effect of *P. gounellei* stem extract against cyclophosphamide-induced DNA damage {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------

Anti-genotoxicity evaluation was performed using animals other than those from the genotoxicity test. Treatments were carried out by administering to the mice (n = 10 per group) the extract (500, 1,000 or 2,000 mg/kg *per os*) or saline solution (negative control) and then CPA (80 mg/kg i.p.) 1 h later. The micronucleus and comet assays were then performed as described above. The anti-genotoxic effect (% reduction) in the micronucleus assay was evaluated according to [@bib34] using the equation:$$\mathit{\%}\text{Reduction} = \frac{PC - T}{PC - NC}x100$$where *PC*, *T*, and *NC* correspond to the mean number of micronucleated cells in the positive control (only CPA), treatment (saline extract), and negative control, respectively.

In the comet assay, the percentage of reduction in genotoxic effect was calculated by the ratio between the score for the extract group and the score for the only CPA group.

2.5. Statistical analysis {#sec2.5}
-------------------------

Normal distribution was verified employing the Kolmogorov--Smirnov test. The data from the comet assay were submitted to one-way analysis of variance (ANOVA) and Tukey\'s test. The data obtained from the micronucleus assay were submitted to ANOVA and linear regression. All tests were performed using the GraphPad Prism 8 software (version 8.0.1) and the significance level was set at p \< 0.05.

3. Results and discussion {#sec3}
=========================

The saline extract of *P. gounellei* stem used here was previously evaluated by thin layer chromatography (TLC) and high-performance liquid chromatography and it was reported the presence of flavonoids at 0.054 g% (including kaempferol derivatives), reducing sugars and a polysaccharide content of 17.17 g%. Alkaloids, coumarins, cinnamic acid derivatives, tannins, terpenes, and steroids were not detected ([@bib21], [@bib20]).

The balance between the therapeutic and toxicological effects is an essential measure to determine the usefulness of a pharmacological drug ([@bib15]). Some plant substances such as alkenyl benzenes, alkaloids and anthraquinone glycosides are known to be potentially carcinogenic and teratogenic ([@bib9]). The *in vivo* micronucleus and comet assays are both considered appropriate for genotoxicity tests in a standard battery for testing pharmaceuticals ([@bib18]).

The clastogenic/aneugenic potential of the *P. gounellei* stem extract was investigated by the micronucleus test ([Table 1](#tbl1){ref-type="table"}). The results showed that treatment with the extract at 500 and 1,000 mg/kg for 24 h did not significantly increase (p \> 0.05) the mean number of MNPCE in bone marrow in comparison with the negative control. On the other hand, a small but significant increase (p \< 0.05) was observed in the MNPCE number in samples collected at 24 h from animals treated with the dose of 2,000 mg/kg compared to the negative control; however, the values were significantly (p \< 0.05) lower than those in the positive control group. As expected, CPA presented an increase in the incidence of micronuclei about 18 times when compared to the control. The micronucleus assay results suggested that the *P. gounellei* extract has no genotoxic effect at doses of 500 and 1,000 mg/kg, however a slight increase in the incidence of micronucleus was observed at the highest dose (2,000 mg/kg). In addition, the cell viability observed in the Trypan blue staining protocol was over 80% in all treatments (data not shown), which confirms the absence of cytotoxicity found by PCE/NCE ratio analysis in the micronucleus test ([Table 1](#tbl1){ref-type="table"}).Table 1Evaluation of *in vivo* genotoxicity of saline extract from *Pilosocereus gounellei* stem extract by determination of the number of micronucleated polychromatic erythrocytes (MNPCE) from bone marrow of mice.Table 1TreatmentsCollection timeNumber of MNPCE per animalMean MNPCEPCE/NCEM1M2M3M4M5*Negative control*24 h110110.8 ± 0.2 a1.16 ± 0.1248 h211011.0 ± 0.3 AB1.21 ± 0.13*Extract (per os)* 500 mg/kg24 h211111.2 ± 0.0 ab1.22 ± 0.0948 h111111.0 ± 0.1 A1.12 ± 0.06 1000 mg/kg24 h111211.2 ± 0.1 bc1.14 ± 0.1048 h101010.6 ± 0.2 AB1.15 ± 0.11 2000 mg/kg24 h222312.0 ± 0.5 c1.16 ± 0.1448 h212221.8 ± 0.4 B1.16 ± 0.11*CPA* 80 mg/kg *i.p.*24 h172422212421.6 ± 2.5 d1.15 ± 0.1648 h201821242221.0 ± 1.8 C1.17 ± 0.15[^1]

The results from the comet assay are shown in [Table 2](#tbl2){ref-type="table"}. For peripheral blood samples collected after 4 h, the cells in the class 0 were predominant in all groups, but the CPA-treated group showed a significantly lower (p \< 0.05) number of undamaged cells and a higher score than the other groups. In the blood samples collected after 24 h, there were no significant (p \> 0.05) differences between the negative control and extract treatments; but CPA genotoxicity was evident, with a damage score of 88.37. With respect to the bone marrow samples, there were also no significant (p \> 0.05) differences in the score between the negative control and the extract group, while the positive control group showed a score of 80.25. The saline extract of *P. gounellei* exhibited antinociceptive and antipyretic activities at doses ranging from 125 to 500 mg/kg b.w ([@bib21], [@bib20]) and the data obtained in this study showed that the extract has no genotoxic effect at these doses and even at higher doses.Table 2Evaluation of *in vivo* genotoxicity of saline extract from *Pilosocereus gounellei* stem extract by comet assay in mice peripheral blood and bone marrow: mean frequency of damaged cells, average distribution per class and average damage score.Table 2SampleCollection timeTreatmentsFrequency^a^Damage classScore0123Peripheral blood4 h*Negative control*1.76 ± 0.7298.24 ± 1.501.76 ± 0.720.-00 ± 0.000.00 ± 0.001.85 ± 0.44*Extract (per os)*500 mg/kg2.00 ± 0.6598.00 ± 0.752.00 ± 0.650.00 ± 0.000.00 ± 0.001.90 ± 0.651,000 mg/kg2.03 ± 0.3297.97 ± 0.472.03 ± 0.320.00 ± 0.000.00 ± 0.002.04-±0.252,000 mg/kg2.16 ± 0.8697.84 ± 0.752.16 ± 0.860.00 ± 0.000.00 ± 0.002.10 ± 0.86*CPA* 80 mg/kg *i.p.*50.92 ± 3.09∗49.08 ± 3.27∗35.17 ± 4.18∗14.42 ± 1.12∗1.33 ± 0.58∗61.49 ± 2.41∗24 h*Negative control*1.88 ± 0.4198.40 ± 0.581.88 ± 0.410.00 ± 0.000.00 ± 0.001.96 ± 0.22*Extract (per os)*500 mg/kg2.00 ± 0.6398.00 ± 0.632.00 ± 0.630.00 ± 0.000.00 ± 0.002.00 ± 0.631,000 mg/kg2.13 ± 0.7697.87 ± 0.222.13 ± 0.760.00 ± 0.000.00 ± 0.002.01 ± 0.762,000 mg/kg2.22 ± 0.5497.78 ± 0.342.22 ± 0.540.00 ± 0.000.00 ± 0.002.13 ± 0.50*CPA* 80 mg/kg *i.p.*80.34 ± 2.49∗19.65 ± 2.17∗70.48 ± 2.49∗7.81 ± 1.07∗2.05 ± 0.61∗88.37 ± 4.04∗Bone marrow24 h*Negative control*1.09 ± 0.1198.91 ± 0.071.09 ± 0.110.00 ± 0.000.00 ± 0.001.20 ± 0.12*Extract (per os)*500 mg/kg1.32 ± 0.5598.68 ± 0.631.32 ± 0.550.00 ± 0.000.00 ± 0.001.25 ± 0.411,000 mg/kg1.28 ± 0.7898.72 ± 0.981.28 ± 0.780.00 ± 0.000.00 ± 0.001.29 ± 0.322,000 mg/kg1.35 ± 0.8698.65 ± 1.781.35 ± 0.860.00 ± 0.000.00 ± 0.001.30 ± 0.65*CPA* 80 mg/kg *i.p.*71.88 ± 3.55∗28.11 ± 4.38∗47.72 ± 4.36∗21.09 ± 2.20∗3.07 ± 1.02∗80.25 ± 5.02∗[^2]

Plants used in traditional medicine have also gained attention due to their potential for the development of chemopreventive drugs ([@bib5]; [@bib16]). Anti-genotoxic properties have been reported for several plant preparations, suggesting their putative protective effect against, for example, dietary carcinogens and inflammatory agents as well as in conjunction with genotoxic chemotherapeutics ([@bib23]; [@bib28]). Our study also investigated the anti-genotoxic potential of the saline extract from *P. gounellei* against cyclophosphamide (CPA), a chemotherapeutic agent that causes genetic damage ([@bib12]).

In the evaluation of the anti-genotoxic effect by the micronucleus assay, the oral administration of different doses of the extract before the CPA injection led to a significant reduction in the frequency of MNPCE in bone marrow compared to that in mice only treated with CPA ([Table 3](#tbl3){ref-type="table"}). The damage reduction ranged from 49.07 to 65.74% in samples collected after 24 h and 54.28%--71.43% in those collected after 48 h. A gradual increase in the extract concentration result in a proportional decrease in CPA-induced clastogenicity, indicating a dose-response relationship.Table 3Evaluation of anti-genotoxic effect of saline extract from *Pilosocereus gounellei* stem extract against cyclophosphamide-induced DNA damage by determination of the number of micronucleated polychromatic erythrocytes (MNPCE) from bone marrow of mice.Table 3TreatmentsExtract doses (*per os*)Collection timeNumber of MNPCE per animalMean MNPCEPCE/NCEReduction (%)M1M2M3M4M5CPA-24 h172422212421.6 ± 2.5 d1.15 ± 0.16-48 h201821242221.0 ± 1.8 C1.17 ± 0.15-Extract plus CPA500 mg/kg24 h12101491011.0 ± 1.3 b1.12 ± 0.0949.0748 h108119109.6 ± 0.6 B1.12 ± 0.0654.28.1,000 mg/kg24 h10910899.2 ± 0.6 b1.14 ± 0.1057.4148 h989988.6 ± 0.6 B1.15 ± 0.1159.05.2,000 mg/kg24 h887777.4 ± 0.5 c1.16 ± 0.1465.7448 h765666.0 ± 0.6 C1.16 ± 0.1171.43[^3]

The comet assay was also used to investigate the ability of *P. gounellei* stem extract to protect peripheral blood and bone marrow cells against CPA-induced DNA damage ([Table 4](#tbl4){ref-type="table"}). The administration of the saline extract before CPA substantially inhibited the damage (p \< 0.05). The DNA fragmentation in peripheral blood cells decreased by 90.53--93.41% in samples collected after 4 h and 85.04--94.44% after 24 h, while in bone marrow the decrease was between 87.43% and 92.70% after 24 h.Table 4Evaluation by comet assay of anti-genotoxic effect of saline extract from *Pilosocereus gounellei* stem extract against cyclophosphamide-induced DNA damage in mice peripheral blood and bone marrow: mean frequency of damaged cells, average distribution per class and average damage score.Table 4SampleCollection timeGroupsExtract doses (*per os*)Frequency[1](#tbl4fn1){ref-type="table-fn"}Damage classScoreReduction (%)[2](#tbl4fn2){ref-type="table-fn"}0123Peripheral blood4 h*Saline plus CPA*-50.92 ± 3.09^a^49.08 ± 3.27^a^35.17 ± 4.18^a^14.42 ± 1.12^a^1.33 ± 0.58^a^61.49 ± 2.41^a^-*Extract plus CPA*500 mg/kg3.67 ± 1.12^b^96.33 ± 3.67^b^3.14 ± 0.79^b^0.53 ± 0.11^b^0.00 ± 0.00^b^4.05 ± 1.01^b^93.411000 mg/kg5.16 ± 1.35^b^94.84 ± 4.93^b^4.58 ± 0.46^b^0.58 ± 0.10^b^0.00 ± 0.00^b^5.79 ± 0.82^b^90.582000 mg/kg5.52 ± 1.20^c^94.48 ± 2.45^c^5.11 ± 0.51^c^0.41 ± 0.03^b^0.00 ± 0.00^b^5.82 ± 1.08^c^90.5324 h*Saline plus CPA*-73.77 ± 1.83^a^18.21 ± 1.35^a^64.66 ± 0.83^a^7.21 ± 1.16^a^1.90 ± 0.33^a^84.83-*Extract plus CPA*500 mg/kg12.69 ± 0.35^b^87.31 ± 5.10^b^12.69 ± 0.35^b^0.00 ± 0.00^b^0.00 ± 0.00^b^12.69 ± 0.35^b^85.041000 mg/kg7.52 ± 0.25^b^92.48 ± 2.48^b^7.52 ± 0.25^b^0.00 ± 0.00^b^0.00 ± 0.00^b^7.52 ± 0.25^b^91.132000 mg/kg5.55 ± 1.02^c^94.45 ± 3.64^c^4.41 ± 1.03^c^1.14 ± 0.62^c^0.00 ± 0.00^c^4.71 ± 0.51^c^94.44Bone marrow24 h*Saline plus CPA*-81.16 ± 6.10^a^16.23 ± 3.41^a^55.11 ± 7.44^a^21.00 ± 5.74^a^5.05 ± 1.14^a^112.26-*Extract plus CPA*500 mg/kg17.51 ± 1.19^b^82.49 ± 3.06^b^15.58 ± 1.06^b^1.93 ± 0.42^b^0.00 ± 0.00^b^14.10 ± 2.05^b^87.431000 mg/kg11.66 ± 1.14^b^88.34 ± 2.77^b^10.74 ± 1.25^b^0.92 ± 0.21^b^0.00 ± 0.00^b^10.26 ± 2.03^b^90.862000 mg/kg7.81 ± 0.82^b^92.19 ± 3.44^b^7.69 ± 1.88^b^0.12 ± 0.06^b^0.00 ± 0.00^b^8.19 ± 1.75^b^92.70[^4][^5][^6]

This ability of *P. gounellei* stem extract to prevent CPA genotoxic effects can be associated to the presence of antioxidants such as flavonoids. The antioxidant properties of flavonoids can lead to inhibition of lipid peroxidation, chelation of redox-active metals, and inhibition of reactive oxygen species ([@bib32]). The presence of flavonoids can even elevate the levels of antioxidant enzymes ([@bib31]). [@bib35] reported that *Opuntia ficus-indica* cladode extract was able to protect Balb/c mice against genotoxicity induced by zearalenone, according to the micronucleus and comet assays. The antioxidant activities of cladode extracts from *O. ficus-indica* have been attributed to significant amounts of polysaccharides, as well as flavonoids and phenolic acids ([@bib26]).

Although the exact mechanism of *P. gounellei* extract in the inhibition of genotoxicity induced by CPA is not completely elucidated, we hypothesize that the antioxidant properties of the extract may explain the protective effects ([@bib20]). It is possible that treatment of animals with the *P. gounellei* extract could improve their antioxidant system, scavenging reactive oxygen species and free radicals generated by CPA and, consequently, reducing chromosome aberrations in somatic cells.

4. Conclusion {#sec4}
=============

The present study was the first *in vivo* evaluation of the genotoxicity of an extract from *P. gounellei*. From our results, it can be stated that *P. gounellei* stem extract, when administered orally at the tested doses, was not genotoxic in peripheral blood erythrocytes and bone marrow cells of mice by the comet assay, but presented aneugenic/clastogenic effects at 2,000 mg/kg dose by the micronucleus test. *P. gounellei* extract also plays a role in inhibiting CPA-induced genotoxicity, including other previously described activities (antinociceptive, antipyretic) which may be related to the main components of the extract and its possible antioxidant activity. Thus, future studies are needed to clarify the mechanisms of action to certify their biological safety and improve human health.
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[^1]: CPA: cyclophosphamide (positive control). In negative control, mice received saline *per os*. PCE: polychromatic erythrocytes. NCE: normochromatic erythrocytes. Different lowercase letters indicate significant (p \< 0.05) differences between the groups regarding samples collected after 24 h. Different uppercase letters indicate significant (p \< 0.05) differences between the groups regarding samples collected after 48 h.

[^2]: In negative control, mice received saline *per os*. (∗) Significantly different from the negative control (p \< 0.001). ^a^Total number of damaged cells (class 1 + 2 + 3). CPA: cyclophosphamide.

[^3]: CPA, cyclophosphamide, was administered at 80 mg/kg i.p. Negative control results can be seen in [Table 1](#tbl1){ref-type="table"}. M (1--5): mice. PCE: polychromatic erythrocytes. NCE: normochromatic erythrocytes. Different lowercase letters indicate significant (p \< 0.05) differences between the groups regarding samples collected after 24 h. Different uppercase letters indicate significant (p \< 0.05) differences between the groups regarding samples collected after 48 h.

[^4]: CPA, cyclophosphamide, was adminestered at 80 mg/kg i.p. In this assay, negative control corresponds to the treatment with saline before CPA administration. For each sample and collection time, different letters indicate significant differences between the treatments (p \< 0.05).

[^5]: Total number of damaged cells (class 1 + 2 + 3).

[^6]: Calculated by the ratio (%) between the score in the extract treatment and that in the treatment with only CPA.
